China Oncology ›› 2018, Vol. 28 ›› Issue (11): 852-857.doi: 10.19401/j.cnki.1007-3639.2018.11.009

Previous Articles     Next Articles

Research progress of biomarkers associated with efficacy of immune checkpoint blockade

ZHAO Haiyun, JI Peng, LI Xiaoguang, HU Xin   

  1. Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Online:2018-11-30 Published:2018-12-14
  • Contact: HU Xin E-mail: xinhu@fudan.edu.cn

Abstract: Cancer immunotherapy has been a novel and efficient cancer therapeutic strategy besides surgery, chemotherapy, radiotherapy and targeted therapy for its durable clinical benefit. Immune checkpoint blockade, as one of the cancer immunotherapy strategies, has been approved for the treatment of many advanced cancers. However, the immune adverse effects and drug resistance are the main challenges limiting its clinical applications. It will be of great significance to explore biomarkers associated with efficacy of immune checkpoint blockade.

Key words: Immune checkpoint blockade, PD-L1, Tumor mutational burden, Commensal bacteria, Haematological biomarker